H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Emergent Biosolutions today and set a price target of $15.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ram Selvaraju has given his Buy rating due to a combination of factors including Emergent BioSolutions’ strong financial performance and strategic positioning. The company reported impressive third-quarter 2025 results, with revenue significantly surpassing expectations and a notable increase in net income and margins. This financial strength has led to an upward revision of their full-year 2025 revenue and profitability guidance, reflecting confidence in continued growth.
Additionally, Emergent’s product portfolio, particularly its naloxone franchise, is well-positioned in the market. The stabilization of pricing for NARCAN Nasal Spray and robust international demand for their medical countermeasures underscore the company’s strategic advantage. The global need for biological threat preparedness further enhances the value of Emergent’s offerings. Valuation analysis using a discounted cash flow model supports a favorable outlook, with a 12-month price target of $15, despite potential risks such as increased competition and challenges in securing government contracts.
In another report released today, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $14.50 price target.